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Summary Information about the costs of recurrent breast cancer is potentially important for targeting cost
containment strategies and analysing the cost-effectiveness of breast cancer control programmes. We estimated
these costs by abstracting health service and consumable usage data from the medical histories of 128 patients.
and valuing each of the resources used. Resource usage and costs were summarised by regarding the
recurrence as a series of episodes which were categorised into five anatomical site-based groups according to
the following hierarchy: visceral, central nervous system (CNS). bone. local and other. Hospital visits and
investigations comprised 7800/ of total costs for all episodes combined, and there were significant differences
between the site-based groups in the frequency of hospital visits and most investigations. Total costs were most
accurately described by separate linear regression models for each group. with the natural logarithm of the
cost of the episode as the dependent variable. and predictor variables including the duration of the episode.
duration squared. duration cubed and a variable indicating whether the episode was fatal. Visceral and CNS
episodes were associated with higher costs than the other groups and were more likelv to be shorter and fatal.
A fatal recurrence of duration 15.7 months (the median for our sample) was predicted to cost S10.575 (Aus S
1988: or £4.877). Reduction of the substantial costs of recurrent breast cancer is likely to be a sizeable
economic benefit of adjuvant systemic therapy and mammographic screening. We did not identify any major
opportunities for cost containment dunrng the management of recurrences.
As health care expenditure escalates. the cost of many health
services is coming under increasing scrutiny (Ginzberg. 1987)
and the need to weigh the costs and benefits of cancer
management. specifically, has been highlighted (Anonymous.
1988: Markman. 1988). A prerequisite for such cost-effect-
iveness analyses is data on health service costs during various
phases of disease. but such information is often difficult to
obtain. The costs of breast cancer recurrences are of partic-
ular interest because breast cancer is the most common
malignancy in women in almost all countries for which inci-
dence figures are available (Waterhouse et al.. 1982). and
relapses occur frequently. In Australia. for example. more
than 5.000 women are diagnosed with breast cancer each
year (Giles et al., 1987). and 5 year mortality rates of 26%
have been reported (Bonett et al., 1988). The fact that
women with breast cancer have a higher mortality rate for 20
years or more after diagnosis has also been documented
(Langlands et al.. 1979). The management of breast cancer
recurrence is therefore a common clinical problem.
The costs of recurrent breast cancer are also relevant to
studies of the cost-effectiveness of methods of controlling
early breast cancer. A major advantage of adjuvant systemic
therapy, for example, is delayed recurrence (Bonadonna &
Valagussa. 1987). Data on the costs of treating recurrent
breast cancer are therefore required to evaluate the cost-
effectiveness of adjuvant systemic therapy. Similarly, such
data would be required to analyse the cost-effectiveness of
mammographic screening, which has been found in some
studies to decrease breast cancer deaths (Tabar et al., 1985).
and hence would presumably decrease or delay recurrences.
The aim of this study was therefore to estimate the health
service costs of treating women with recurrences of breast
cancer, and to investigate factors predicting costs.
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Methods
The study was conducted in two major Melbourne cancer
treatment hospitals. which together accounted for 58% of
public hospital admissions for breast cancer in the state
of Victoria in the financial year 1986-87 (Health Department
Victoria. unpublished data). Public hospital services in Victoria
are mostly provided free of charge to patients and are funded
through a complicated state and national government cost-
sharing agreement. This study was confined to hospital-based
health service costs, as patients who attend public hospitals
for cancer treatment in Melbourne usually receive most of
their care from this source. In addition to inpatient care.
hospitals provide medical consultations, investigations, drugs
and paramedical services to outpatients. Patients who are
terminally ill, but are not admitted to hospital. often receive
nursing care from a home visiting service, but this care was
not costed.
Identification and valuation ofhealth service resources
Costs were estimated by first identifying the number and type
of health services used by a series of patients. valuing each
type of service and then summing the costs. A series of 128
women were identified who had presented with recurrent
breast cancer to the study hospitals. Sixty-three women from
one hospital represented a consecutive series of patients who
had received adjuvant chemotherapy in 1982-85 and had
subsequently relapsed. and the 65 women from the other
hospital were a consecutive series of patients who presented
with a first recurrence in 1983-84. We believe our sample to
be representative, as it comprised two consecutive series from
hospitals with large cancer patient loads.
Information on the number and type of all health service
resources used was abstracted from each patient's medical
record by a trained abstractor from the time recurrence was
first diagnosed until either the patient died (89 cases) or no
further information was available. Six of the 89 patients who
died were admitted to a hospice or a private hospital affiliat-
ed with the initial treating hospital in the weeks or months
before their deaths, and in these cases the patient's medical
record was abstracted at the second institution. If the patient
was still alive at the time of history abstraction the data were
regarded as censored, i.e. complete information about the
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recurrence from diagnosis to death was not available because
sufficient time had not elapsed.
It was necessary to make some simplifying assumptions in
order to summarise the resource usage and cost data. The
concept of a recurrence episode, defined as a time period
during which metastatic disease was known to involve a
specific set of anatomical sites, was used. Anatomical sites
were grouped into the five classifications shown in Table I
because imiilr classifications of recurrences have been
reported previously (Goldhirsch et al., 1988; Kamby et al.,
1988) and because of an a priori expectation that treatment
for sites within the groups would be similar. In general,
treatments of choice for each site group were thought to be:
hormonal and/or cytotoxic chemotherapy for visceral; radio-
therapy for CNS; hormonal therapy, then cytotoxics in non-
responders, for bone; surgery and radiotherapy (sometimes
with cytotoxics) for local; and cytotoxics ± radiotherapy for
the other group. Each episode finished when involvement of
a site from another group was diagnosed, or the patient died,
or history abstraction ceased. For example, an episode invol-
ving the mastectomy scar and regional nodes was classified as
'LM'. Ifliver metastates were diagnosed the patient was then
regarded as having a new episode, classified as 'VLM'. For
each episode, the number and type of each health service or
consumable used, the sites involved, and the duration and
reason for cessation of the episode, were noted.
A further simplification of recurrence classification was
used in many analyses. Each episode was categorised in a
hierarchical manner to one of five groups according to the
order in which the site groupings are listed in Table I. Group
1 consisted of all episodes involving visral sites; Group 2
consisted of all episodes that involved CNS ± other sites
except visceral; Group 3 consisted of all episodes involving
bone ± other sites except visceral or CNS; Group 4 consisted
of all episodes involving the sites classified in Table I as
local ± other sites except visceraL CNS and bone; and the
last group (5) consisted of episodes involving only the 'other'
sites listed in Table I. In the above example, the first episode
would have been classified as Group 4, and the second
episode as Group 1.
Although services and consumables were used over a
period of years, starting in 1982, all resources were valued at
1988 prices (in S Aus). Costs were not discounted because of
the short time period over which they were incurred. The
costs ofthreetypesof hospital visit - an inpatientday, a
daypatient attendance and an outpatient attendance were
calculated. A daypatient attendance was defined as a hospital
visit where the patient was not admitted to a ward, but either
chemotherapy was administered, or a procedure - abdominal
or thoracic paracentesis, blood transfusion, lumbar puncture,
urinary catheterisation or bone marrow biopsy - was per-
formed. An outpatient attendance was an ambulatory visit
which did not involve chemotherapy or a procedure. Costs
for these visits were caculated by apportioning oncology unit
and ward nursing staff costs to each type of visit on the basis
of nursing dependency data for cancer patients and an
activity study of the oncology unit; 'hotel costs' (administra-
tion, cleaning, food, power, maintenance and medical record
services) were apportioned on a per diem basis equally to all
Table I Anatomical site classifications
Cla.sification Anatomical sites
Visceral (V) Lungs, liver, pleura,
abdomen, bone marrow
CNS (I) Central nervous system
(including eye)
Bone (E) Skeletal bone
Local (L) Chest wall, mastectomy
scar, contralateral breast
Other (M) Regional (axillary, internal
mammary or supraclavicular
nodes), other nodes, soft
tissue, any other site.
hospital patients (irrespective of diagnosis) within the three
categories of hospital visit. In this manner costs of $261.30,
$88.90 and $75.80 were derived for an inpatient day, out-
patient attendance and daypatient attendance, respectively.
These figures excluded investigations, drugs, radiotherapy
and paramedical or medical services not supplied by the
oncology unit. The majority of daypatient visits were for
chemotherapy, which involved less medical staff time than an
outpatient visit, hence the cost of daypatient visits was lower.
Capital depreciation ofbuildings is not included in Victoria's
public hospitals' accounting systems, and was therefore not
included in these costs.
The clinical costing system of another Melbourne hospital
(Gray et al., 1987b, 1988) was used to value investigations.
With this system, all recurrent operating expenditures are
allocated to units of output on a monthly basis; capital
depreciation of equipment is not included. Salary expendi-
tures are apportioned to individual tests using the relative
values for staff time; consumables are allocated on the basis
of their actual costs; and overheads are allocated equally to
all tests. Relative values for staff time had been derived for
organ imaging and laboratory tests using the Program Evalu-
ation and Review Technique (PERT) (Gray et al. 1987b) and
the College of American Pathologists' workload recording
system (Gray et al., 1988), respectively. We used the mean
cost of each investigation over the 6 month period, January
to June 1988. Hospital overheads (administration, power,
etc.) were excluded to avoid double counting.
Drug costs comprised the cost of the actual drug plus
pharmacy preparation costs. Hospital wholesale drug prices
were used for the former, and the latter were estimated by
apportioning total annual pharmacy department costs from
one hospital to each workload item, using estimated dispens-
ing time as a relative value. The only medical staff costs
included in the hospital visit costs were those of the oncology
unit, and therefore Medicare benefits schedule fees (set by the
Australian national health insurance organisation) were used
for radiotherapy, and the medical component of any surgery
and associated anaesthesia.
Analysis
Resource usage and costing data were entered on a custom-
ised INGRES database and analyses were performed using
the Strutured Query Language (SQL) and the statistical
computing package MINITAB. Costs were disaggregated
into hospital visits (outpatients and daypatients were com-
bined and summarised as ambulatory visits), investigations,
radiotherapy, drugs, and other costs. Drugs costs were sub-
divided into cytotoxics, hormonal drugs, and other drugs,
and each group was further subdivided into the costs of the
drug itself and preparation costs.
A large number of factors had the potential to affect costs,
including duration of the recurrence, anatomic sites involved
and the patient's age. It was not feasible to present multiple
tabulations of costs categorised according to these factors,
and a regression approach was therefore used to determine
the factors affecting total costs. Stepwise regression analysis
was conducted with both F to enter and F to leave set to
four. The dependent variable was taken to be the natural
logarithm of cost, In(cost). Two separate sets of analyses
were performed, the first with ln(cost) for each recurrence
episode as the dependent variable, and the second with
!n(cost) for the total recurrence (i.e. per patient rather than
per episode). The predictor variables considered included
duration, duration squared and duration cubed, whether or
not the recurrence episode (or recurrence for the second
analysis) was fatal, five age categories (<39, 40-49, 50-59,
60-69, and >70 years), past and present sites of recurrence,
and whether the episodes (or recurrence) was censored. The
choice of transformation for the dependent variable, and
inclusion of duration squared and cubed as potential predic-
tor variables, was based on an observed polynomial pattern
when ln(cost) was plotted against the duration of the re-
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currence as potential predictor vanables allowed for the
possibility that the costs of an episode would vary with past
site involvement or any of the sites involved in the current
episode. Duration was measured in hundreds of days for the
regression analyses.
Results
Patients and recurrence details
The mean age of patients at the onset of recurrence was 52.9
years (95% CI 51.1. 54.8: median 54.4). The mean duration
from the time breast cancer was first diagnosed until recur-
rence occurred was 27.5 months (95% CI 23.8. 31.1: median
21.7). The 128 women experienced 261 recurrence episodes. a
mean of 2.07 per patient (maximum 5). Resource usage, costs
and duration of the recurrence episodes all had skewed distri-
butions. and therefore medians were mainly used as measures
of central tendency. The median duration of the total recur-
rence per patient was 17.8 months (15.7 months for those
who died, 29.5 months for those for whom data were censor-
ed). Of the 261 recurrence episodes. 102 were categorised as
Group 1 (visceral). 23 were Group 2 (CNS). 69 were Group 3
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Resource usage patterns
For each episode. the number of each type of health service
used per 3 months was calculated. If the duration of the
episode was less than 3 months, the actual number of services
was used for the analysis. The usage patterns for each type of
service were compared for the different site-based groups
using the Kruskal-Wallis non-parametric rank test. The
number of inpatient admissions, inpatient bed days (the sum
of the lengths of stay for all admissions) and number of
daypatient visits differed significantly between the five groups
(P = 0.0031. 0.0011 and 0.0002. respectively). but the number
of outpatients Visits did not. The distributions of inpatient
days. outpatients visits and daypatient attendances are shown
as box plots in Figure 1.
The unit costs, and median and 75th percentiles of the
number of tests per 3 months for the most frequently used
investigations are summarised in Table II. There were signi-
ficant differences between groups in the median frequency of
use for all tests. except carcino-embryonic antigen assays and
nuclear medicine investigations.
There were also differences between the site groups in
radiotherapy and cytotoxic drug treatment patterns over the
duration of the episode. Radiotherapy was used more com-
monly in Group 5 episodes (which included sites with nodal
involvement), and least frequently during Group 1 episodes.
One or more radiotherapy treatments were used during
21.6%. 52.2%. 49.3%. 43.2% and 70% of episodes from
Groups 1-5 respectively. Cytotoxics were more commonly
prescribed for visceral episodes, followed by 'other', local.
bone and CNS. Approximately 65% of visceral episodes
involved treatment with a cytotoxic drug. compared with
46.7% of episodes from the 'other' group. 42% of bone. 27%
of local, and 17.4% of CNS episodes. Tamoxifen was pre-
scribed during 52.2% of bone. 28% of visceral, 26.7% of
'other'. 21.6% of local and 8.7% of CNS episodes. These
treatment patterns were therefore similar to the expected
treatment patterns described in the Methods section.
Costs
The median (75th percentile) cost per episode for all episode
groups combined was $4,295 ($10,124) and the median cost
per recurrence was $11.349 ($18,258). For the 89 patients
who died, the median cost per recurrence was S11,948
($18,771). The median and 75th percentiles for the total and
component costs per episode per month, for each of the five
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Figure 1 Box plots of the number of inpatient days. outpatient
attendances and daypatient attendances per 3 months for each of
the episode groups. These plots display data values from the 25th
to the 75th percentile as a box. with the median value as a
horizontal bar. The range of the remaining data is represented by
bars which extend from the box to the nearest data point below a
distance 1.5 times the interquartile range. Observations lying
outside this range are shown as individual points.
for visceral and CNS recurrence episodes were substantially
higher than for bone. local or 'other' recurrences. As noted
above, the cost distributions were skewed to the right, due to
a few high cost outliers, and therefore mean costs were
higher than median costs. For Groups 1-5. and all episode
groups combined, mean total monthly costs were S2,148.
$2,163. S723. $836, $838 and S1,436. respectively.
For each group, hospital visits and investigations were the
largest and second largest components of total costs, respec-
tively. Hospital visits comprised 53.8% of mean total costs.
and investigations 24.2% for all episodes combined. Prepara-
tion costs comprised only 15.7% of mean monthly total drug
costs. Radiotherapy costs were a very small component of
total costs for all groups except Group 2 (CNS) and Group 5.
Regression analyses
The first regression analysis. where recurrences were con-
sidered in terms of episodes. and all episodes were included
in the analysis. yielded the following equation (With
= 48.9%).
;
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Table n Unit costs and median frequenc-v of use per 3 months for common investigations
Medran (75th percentile) number per 3 months
Group
U-nit cost
Investigation S 1 ' 3 4 5 All groups
Urea and electrolvtes 4.14 3.4 (5.1) 2.0 (3.6) 20(2.9) 1.2 (2.6) 1.8 (3.3) 2.1 (3.9)
Full blood examination 15.69 4.0 (6.0) 2.0 (3.5) 2.0 (3.1) 1.4 (2.8) 2.0 (4.7) 2.3 (4.6)
Liver function test 13.16 3.0 (4.8) 2.0 (2.7) 1.9 (2.9) 1.2 (2.6) 1.7 (3.1) 2.0 (3.5)
Carcino-embryonic antigen test 7.60 1.0 (2.0) 0 (1.6) 0.9 (2.0) 1.0 (1.5) 0.7 (1.6) 1.0 (1.9)
Nuclear medicine
bone stud+ 187.50 0 (0.5) 0 (0.2) 0.1 (0.5) 0.3 (0.9) 0.2 (0.6) 0.1 (0.5)
liver study 193.12 0 (0.6) 0 (0) 0 (0.3) 0 (0.2) 0 (0.3) 0 (0.3)
Chest X-raV 42.30 1.0 (20) 0 (1.0) 0.3 (0.7) 0.6 (1.0) 0.6 (1.0) 0.6 (1.1)
Bone X-rav - 0 (0.8) 0 (0.4) 0.5 (1.0) 0 (0.7) 0 (0.5) 0 (0.8)
Computed tomographya 0 (0.6) 0.4 (1.1) 0 (0.1) 0 (0.2) 0 (0.6) 0 (0.4)
aCost varied with region examined; The price of a skeletal survey. for example. was S81.40 and computed tomography ofthe chest was $309.46.
Table Ill Median monthl- costs of episodes for site-based groupsa
fedian costs per month (Sv
Group
Components 1 2 3 4 .411
ofcosts visceral, CNVS bone local (other) groups
Hospital *isits
Inpatient stays 164 (697) 172 (2125) 13 (285) 0 (50) 38 (277) 34 (461)
Ambulators. Visits 154 (236) 139 (220) 101 (155) 108 (204) 113 (182) 129 (210)
Total 380 (946) 300 (2171) 162 (438) 165 (439) 173 (508) 249 (700)
Investigations 199 (322) 180 (294) 101 (149) 114 (309) 126 (222) 138 (282)
Drugsv
Cv-totoxics 66 (196) 0 (0) 0 (37) 0 (40) 0 (98) 0 (103)
Hormonal 0 (2) 0 (0) 2 (8) 0 (7) 0 (0) 0 (4)
Other 16 (43) 20 (49) 6 (35) 2 (15) 4 (20) 0 (35)
Total 115 (255) 29 (85) 43 (120) 11 (76) 23 (154) 52 (157)
Radiotheraps 0 (0) 53 (237) 0 (78) 0 (76) 68 (147) 0 (73)
Other 0 (17) 0 (6) 0 (11) 0 (13) 0 (4) 0 (9)
Total 909 (1781) 1093 (2606) 457 (798) 533 (966) 557 (1125) 596 (1351)
'75th percentile in brackets: bCosts have been rounded to the nearest dollar; cFigures include drug and
preparation costs.
In(cost) = 6.62 + 0.816 dur- 0.085 dur' + 0.00266
dur3 + 0.727 dead + 0.374 presi
where dur = duration of the episode in hundreds of days.
dead = I if the episode was fatal; 0 otherwise; presi= 1 if
CNS was involved in the current episode: 0 otherwise.
This indicated that costs were predicted by the duration of
the episode. and duration squared and cubed, whether the
episode was fatal and CNS involvement in the present
episode. All predictor variables were significant at P<0.001.
except presi. which was marginally, significant (P = 0.051).
The predicted costs for fatal and non-fatal recurrence
episodes (without CNS involvement) are plotted on a loga-
nthmic scale for a period of 2,000 days in Figure 2. The
presence of duration cubed in the regression equation is
needed to explain the flattening out of ln(cost) for episodes
of longer duration. This cubic term makes estimation ofcosts
outside the range considered quite unreliable.
The model predicted that a non-fatal recurrence episode of
duration 7 months (213 days) would cost 52.988 ($227).
increasing to $6,185 (S634) if the recurrence was fatal, and to
$8,991 ($1675) if a CNS site was involved (approximate
standard errors in brackets). In companrson, the actual
median cost for a 7 month recurrence episode, considering all
groups, was $4,172 (Table III). When we consider that 41.2%
of episodes were fatal, an approximate predicted cost is
52.971 x (0.588) + $6,105 x (0.412) = $4,262.
Although this example suggests that the model predicted
costs well, apart from presi, none of the variables indicating
current or past site involvement were included. Table IV
provides an explanation for the absence of these variables. It
shows that the duration and the outcome of the episode were
highly correlated with sites. The median duration and pro-
portion dying in each group were both significantly different
(P<0.001, Kruskal-Wallis test and x test for independence,
respectively). The visceral and CNS episode groups were
more likely to be shorter and fatal. We therefore undertook
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Figure 2 Predicted costs (on a logarithmic scale) for fatal and
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Table IV Duration and outcome of recurrence episodes. by Group
Group
1 2 3 4 5
No. of episodes 102 23 69 37 30
Median duration 5.1 3.3 11.2 10.8 7.5
(months)
No. of fatal episodes 51 15 14 3 6
(C0) (50) (65.2) (20.3) (8.1) (20)
categorised into one of the five site-based groups in the
hierarchical fashion described above, and the costs for each
group considered separately. The dependent variable was still
the in(cost) of a recurrence episode. and past sites and other
sites involved in the current episode were included as poten-
tial predictor variables. For example. a recurrence episode
involving the liver and central nervous system was classified
as Group 1. but CNS involvement was considered as a
potential predictor of costs.
The results of these analyses are summarised in Table V.
Similar models were obtained for visceral, bone and local
groups. except that for the bone group. costs were predicted
to be lower for women aged 60-69 than for other women.
For the 'other' group. the model indicated an increase in
costs with duration and previous bone recurrence. and a
decrease in costs for women aged 70 and over. In the CNS
group. none of the potential predictor variables were found
to be significantly related to in(cost,. The r for each of these
models were higher than for the model in which all episodes
were considered together.
The next set of regression analyses were conducted with
in(cost) for the total recurrence as the dependent variable.
The duration was for the total recurrence. and site variables
described the sites involved in the first and final episode for
each patient. The following model was derived when all cases
were considered:
In(cost) = 7.38 + 0.415 dur - 0.0266 dur + 0.000542 dur' +
0.454 dead + 0.495finali
where finali = 1 if CNS was involved in the final episode: 0
otherwise.
The r was 43.6%. This model predicted that a fatal recur-
rence. without CNS involvement, of 15.7 months' duration
would cost S10.575 (S872). Separate analyses were then con-
ducted for each of the five site-based groups. categorised on
the basis of sites involved when the recurrence was first
diagnosed. The models derived were similar to the episode-
based models summarised in Table V. except that duration
squared terms were not included, the r values were smaller.
and predictor variables were only significant at P< 0.05.
This study has pro'ided an estimate of the costs of managing
recurrences of breast cancer. More explanatory models of
cost were derived by considering recurrences in terms of
episodes. rather than in total. and accuracy improved further
if episodes were classified into groups on the basis of site
involvement. All cost prediction models - for episodes.
groups of episodes and patients - were dependent in a com-
plicated fashion on the duration of the episode or recurrence.
With increasing duration. the costs of episodes followed a
cubic pattern. Costs initially increased as the duration of the
episode increased. but flattened off as duration increased
further. This probably reflected high costs for an episode of
short duration associated with investigations and initiation of
treatment, and declining costs once disease stabilised. Fatal
recurrences were more costly than non-fatal recurrences. as
might have been predicted. Visceral and CNS recurrences
were more costly than those involving other sites and were
more likely to be fatal. There was some evidence that recur-
rences in older woman were less expensive. presumably
because of less intensive treatment. Although the censoring
of some data could have resulted in under-estimation of
costs. any such effect appeared to have been slight because of
the lack of significance of the censoring variable and inc-
lusion of duration in the regression models.
The difficulties in measuring the costs of health services are
well recognised and deficiencies in cost databases in the UK
and US have been described (Weinstein. 1989; Rees. 1985).
Within the Australian health care system. 'true' costs are
difficult to derive because of the poorly developed state of
most hospital's clinical cost accounting systems. The comput-
rised clinical costing systems which have been implemented
are inpatient-based (Stoelwinder et al.. 1987). and therefore
unsuitable for costing disease episodes which involve a mix of
inpatient and ambulatory management. Costing studies are
therefore laborious and subject to criticism. However. we
believe that the management patterns for our sample repre-
sented normal clinical practice in Melbourne and that we
estimated the costs of breast cancer recurrences as accurately
as is possible within the constraints of available data.
Resource usage data were obtained by a trained medical
record abstractor. and the standard of medical record keep-
ing at participating hospitals was believed to be good. as
both hospitals were actively involved in clinical trials and
recorded treatment information in a uniform format. Never-
theless. the possibility that patients' histories provided an
incomplete record of resource usage has to be considered. It
was extremely unlikely that hospital visit data would be
incomplete and most test results were reported on cumulative
sheets. Anv reference bv a doctor in the narrative section of
the patient's history to an investigation, without a corre-
spondinr result. was clarified with the relevent hospital
department. Inpatient and cytotoxic drug therapy was
recorded on medication charts. and a duplicate of each out-
patient prescription was filed in the history. Recording of
consultations With paramedical staff may have been incomp-
lete. but as these services comprised only a small portion of
total costs. any under-estimation would have had only a very
minor impact on total costs.
Valuation of services and consumables involved a number
of assumptions. As hospital visits were the single largest
component of costs. the methods used for their estimation
potentially had a large impact on costs. We assumed that
there was no difference in the cost of hospital visits for breast
cancer patients and other oncology patients. and that the
Table V Summary of regression analysis for grouped episode data
.N'o. of Coefficients for:
Group cases r Intercept dur dur- dur3 dead age 4 age5 paste presi
I 102 53 6.45 1.18 -0.177 0.00841 0.731 1.81
2 23 - - - - _ _ _
3 69 53 6.86 0.643 -0.0547 0.00151 0.793 -0.587
4 37 75 6.27 1.16 -0.154 0.00558 - - -
5 30 63 7.46 0.204 - - -3.26 1 1.10
where r = the proportion ofvariation In (cost) explained; dur and deadas previously defined:
age 4 = 1 ifaged 60-69years. 0otherwise: age5 = I ifage > 70 years. 0 otherwise:paste = bone
involvement in a previous episode: presi = CNS involvement in the current episode454 S.F. HURLEY et al.
cost per inpatient day was the same for each day of admis-
sion. Allocation of hotel costs on a per diem basis assumed
that administrative and support service costs and overheads
were constant within the three categories of hospital visit.
More rigorous methods of estimating such costs (for exam-
ple. simultaneous allocation to adjust for interaction between
overhead departments) have been described (Drummond et
al.. 1987). but were not feasible in this instance because of a
lack of data. Also. as previously noted. Victoria's public
hospital accounting systems are largely cash-based. and
therefore our estimates did not include the cost of capital
consumed through depreciation of hospital buildings and
laboratory and imaging equipment. or the cost of financing
the investment of these capital items. A recent Australian
survey. in which buildings and equipment for a sample of
hospitals were valued at current replacement costs. suggests
that depreciation and financing of capital items each repre-
sent around 8% of gross operating costs in similar hospitals
to those we studied. assuming a 500 real annual interest rate
on capital (Dr John Deeble. National Centre for Epidemio-
logy and Population Health. unpublished data). Therefore.
we underestimated total hospital-based health service costs
by around 16% due to exclusion of capital costs. Notwith-
standing these limitations. our method yielded more credible
estimates of costs than either charges or per diem allocation
of all hospital costs.
We are not aware of anv other studv which has estimated
the costs of recurrent breast cancer in a similar manner.
Baker et al. (1989) in the USA used Medicare data to
estimate the cost of terminal care. defined as the sum of
charges billed to Medicare in the last 6 months of life. The
mean charges for 2.780 women with breast cancer were
S15.136 (SUS. 1984). excluding drugs. Long et al. (1984) also
used health insurance claims data for 235 women and esti-
mated that the mean expenditure during the last 6 month's of
life was S14.545 (SUS. 1980). Conversion of these estimates
to 1988 SAus using the medical care consumer price indices
for Australia and the USA and the 1985 medical and health
care purchasing power paritx (Organisation for Economic
Co-operation and Development. 1985). yields S21.706 and
S29.742. respectively. Our estimate of S10.575 for care of a
terminal recurrence of median duration is considerably lower
than either of these values, and the disparity is likely to be
due to different treatment patterns. as use of the purchasing
power parity conversion supposedly adjusts for differences in
health care prices between Australia and the USA. Marked
regional and international differences in the management of
patients with cancer have previously been noted. Aaron and
Schwartz (1984). for example. described major differences
between the USA and the UK in the management of cancer.
and Long and colleagues found stnrking differences in
resource utilisation. and therefore costs. between samples of
patients with terminal cancer in Michigan and Indiana
(McArdle et al.. 1981). Application of the cost functions
derived in this paper to other health care settings would
clearly be dependent on similarity of treatment patterns. and
the resource usage data summarised in Figure 1 and Table II
should enable clinicians to compare. in general terms. their
practices with those of oncologists in Melbourne.
The cost and resource usage data derived in this study can
be used in two ways - to audit management practices with a
View to cost containment. and to analyse the cost-effec-
tiveness of breast cancer control strategies. Annual Aus-
tralian cancer deaths have been predicted to increase by
58-70% between 1980-84 and 2004 because of population
ageing and declining cardiovascular mortality rates (Holman
et al.. 1987). If this prediction proves correct, the demand for
terminal cancer care will increase, and. combined with ad-
vances in diagnostic technology. this will result in substantial
increases in cancer care costs. Reviews of patterns of care.
aimed at reducing unnecessary expenditures would therefore
be expedient. but a major difficulty is that consensus on the
optimal management of breast cancer. and other cancers.
does not exist (Anonymous. 1988).
In our study the two largest components of costs were
hospital visits and investigations. Although savings might be
anticipated if some inpatient care could be shifted to ambu-
latorx settings. a previous study comparing the costs of
terminal cancer care for home hospice patients and patients
managed traditionally suggested that major savings would be
unlikely (Gray et al.. 1987). at least in the terminal phases of
illness. This Western Australian study found that the mean
cost of care per patient during the last 90 days of life was
approximately equal for 98 patients who were cared for by a
home-based hospice service and a group of control patients
sho received traditional institutional care.
A reduction in investigation rates, then. provides the main
opportunity for cost containment. Brewin (1981) has ex-
pressed the view that patients with advanced cancer undergo
too manv tests - particularly computed tomography. X-rays
and isotope scans - with little chance of treatment plans or
prognosis altering as a result. Are the investigation rates in
our study justified. considering that the management of
recurrent breast cancer (apart from isolated local recurrences)
is palliative? Table II indicates that baseline investigations
were performed approximatelv every 2 months. and carcino-
embrvonic antigen tests were performed around once every 3
months. The unit costs of these tests wrere small. and such
investigation rates would be easilv justified. even in the con-
text of palliative care. The table also indicates that isotope
and computed tomography scans were performed relatively
infrequently. When all recurrence episodes were considered.
48.30o of episodes did not involve a bone study. 62.1Oo did
not involve a lung study and 60.2006 involved no computed
tomography scans. These investigation rates suggest that
there would be little potential for cost saving. However.
interactions between treatment. especially with cvtotoxics.
and the frequency of hospital visits and investigations were
likely. Active therapy required monitoring and consultations.
with little opportunity for cost-saVing. Our study did high-
light one area where costs might be contained - a reduction
in the medical component of hospital visits, as demonstrated
by the lower unit cost of day-patient compared with out-
patient Visits.
The second use of data on the costs of breast cancer
recurrences - for analyses of the cost-effectiveness of breast
cancer strategies. such as adjuvant systemic therapy and
mammographic screening - is equall important. Eddy used
Baker and colleagues' estimate of the costs of terminal illness
in an analysis of the cost-effectiveness of mammographic
screening in women aged under 50 years (Eddy. 1988). and
cost functions such as we report would be particularly useful
for analysis of the cost-effectiveness of adjuvant systemic
therapy. where a delay until recurrence is a major benefit.
In summary, we conducted a careful studs of the costs of
breast cancer recurrences bv recording and valuing health
service usage over the duration of the illness. Models describ-
ing cost as a function of duration, site involvement and the
outcome of the recurrence were derived. The models were
plausible and explained a large proportion of the inter-
patient variation in costs. Studies such as this can provide a
valid basis for audit of cancer care and cost-effectiveness
analysis.
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